cost-effectiveness

Atrial fibrillation (AF) prevalence is on the rise, increasing 13% over the last twenty years in the United States alone. Its incidence is expected to
When a drug or medical device becomes available in the marketplace, few if any experts (including doctors) or individual patients question its price. In her article in the NYTimes,